[Form 4] Genpact LTD Insider Trading Activity

Rhea-AI Filing Summary

Insider transactions by Genpact Ltd director and CEO Balkrishan Kalra. On 09/11/2025 Mr. Kalra sold 15,000 common shares at a weighted-average price of approximately $43.39 and sold 40,000 common shares at a weighted-average price of approximately $43.35, reducing his reported beneficial ownership to 295,246 shares. On the same date he acquired 40,000 common shares by exercising employee stock options at a $27.65 exercise price, bringing his beneficial ownership to 335,246 shares before the net sales shown. The Form 4 shows the option originally vested in two tranches (50% on 01/10/2019 and the remainder on 01/10/2021) and lists 40,000 underlying shares exercised with 2,800 derivative securities remaining reported as beneficially owned. Transactions were signed by an attorney-in-fact on 09/15/2025.

Positive

• Transparent disclosure of option vesting dates and weighted-average sale price ranges with offer to provide per-share sale prices on request
• Exercise of employee stock options at a reported $27.65 price, converting compensation into equity

Negative

• Insider sold 55,000 shares on the same day as the exercise, which reduced reported beneficial ownership from 335,246 to 295,246 shares

Insights

Securities/Insider Transactions Analyst

TL;DR: Insider exercised 40k options at $27.65 and sold 55k shares at ~$43.35–$43.39 on 09/11/2025.

The filing documents a contemporaneous option exercise and open-market sales by a named executive and director. Exercising 40,000 options at $27.65 converted employee stock options into common shares, followed by sales totaling 55,000 shares at weighted-average prices around $43.35–$43.39. The report shows reported beneficial ownership levels of 335,246 and 295,246 shares after the respective acquisition and sales entries. These are routine Section 16 transactions: the exercise captures intrinsic value between exercise price and sale price, and the Form 4 discloses the weighted-average sale price ranges per the explanation. No other compensatory or extraordinary terms are disclosed in this filing.

Corporate Governance Specialist

TL;DR: Transactions are disclosed cleanly; vesting history is provided, no governance red flags shown.

The filing identifies the reporting person as both President & CEO and a director, and it documents vesting dates for the option grant (50% vested 01/10/2019, remainder 01/10/2021). The Form 4 was executed by an attorney-in-fact and includes weighted-average price ranges for the sales, with an explicit offer to provide per-share sale price breakdown on request. Nothing in the form indicates undisclosed related-party transfers or material omissions within the scope of the reported transactions.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kalra Balkrishan

(Last) (First) (Middle)

C/O GENPACT LLC

521 FIFTH AVENUE, 14TH FLOOR

(Street)

NEW YORK NY 10175

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Genpact LTD [ G ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

3. Date of Earliest Transaction (Month/Day/Year)
09/11/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	09/11/2025		S		15,000	D	$43.39(1)	295,246	D
Common Shares	09/11/2025		M		40,000	A	$27.65	335,246	D
Common Shares	09/11/2025		S		40,000	D	$43.35(2)	295,246	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (Right to Buy)	$27.65	09/11/2025		M			40,000	(3)	03/31/2026	Common Shares	40,000	$0	2,800	D

Explanation of Responses:

1. The price in Column 4 is a weighted average price. The actual sales prices for these transactions ranged from $43.39 to $43.40. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

2. The price in Column 4 is a weighted average price. The actual sales prices for these transactions ranged from $43.29 to $43.42. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

3. The option vested 50% on January 10, 2019 and the remainder on January 10, 2021.

Remarks:

	/s/ Thomas D. Scholtes, as Attorney-in-fact for Balkrishan Kalra	09/15/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Genpact (G) insider Balkrishan Kalra do on 09/11/2025?

On 09/11/2025 Mr. Kalra exercised 40,000 options at $27.65 and sold 55,000 common shares (15,000 and 40,000) at weighted-average prices near $43.39 and $43.35 respectively.

How many Genpact shares did Kalra beneficially own after the reported transactions?

The Form 4 reports beneficial ownership figures of 335,246 shares after the acquisition entry and 295,246 shares after the sales entries.

What was the exercise price and vesting history of the options exercised by Kalra?

The exercised employee stock option had an exercise price of $27.65; it vested 50% on 01/10/2019 and the remainder on 01/10/2021.

Are the reported sale prices exact?

The filing states the sale prices are weighted-average prices and provides ranges: for the 15,000-share sale prices ranged $43.39–$43.40; for the 40,000-share sale prices ranged $43.29–$43.42. The filer offers to provide exact per-share sale counts on request.

Who signed the Form 4 for Balkrishan Kalra?

The Form 4 was signed by Thomas D. Scholtes as attorney-in-fact for Balkrishan Kalra on 09/15/2025.